Возможности патогенетической терапии новой коронавирусной инфекции

Abstract

Aim: to assess clinical efficacy of azoximer bromide in the complex inpatient treatment for COVID-19. Patients and Methods: the study included 20 patients aged 16–65 years with verified moderate novel coronavirus infection who received inpatient care. All patients were divided into two groups. Study group patients (n=10) received complex treatment that included azoximer bromide. Control group patients (n=10) received standard therapy only. The criterion of treatment efficacy was the improvement of major disease symptoms, radiographic manifestations, and pro-inflammatory laboratory tests. Results: azoximer bromide as a component of the treatment for novel coronavirus infection provides more rapid symptom relief (i.e., cough, sputum, fever, respiratory rate) compared to the standard therapy (p<0.05). azoximer bromide also provides more rapid radiographic improvement as demonstrated by helical computed tomography, i.e., by day 14, the percentage of lung parenchyma involved was 5% in the study group and 10–12% in the control group (p<0.05). In addition, the improvement of pro-inflammatory laboratory tests (i.e., normal WBC count, decrease in ESR) was revealed as well (p<0.05). Conclusion: azoximer bromide as a component of the complex treatment for novel coronavirus infection is associated with the clinical improvement that manifests with more rapid relief of inflammation and lung parenchyma involvement as compared with the standard therapy. No adverse reactions were reported. KEYWORDS: coronavirus infection, SARS-CoV2, COVID-19, pneumonia, immune correction, pathogenetically-oriented therapy, azoximer bromide. FOR CITATION: Mukhamadieva L.R., Mavzyutova G.A., Tyurina E.B., Kuzovkina O.Z. Pathogenetically-oriented therapy for novel coronavirus infection. Russian Medical Inquiry. 2020;4(4):192–198. DOI: 10.32364/2587-6821-2020-4-4-192-198.